Vitamin E and smokers
This article was originally published in The Tan Sheet
Higher baseline serum alpha-tocopherol concentrations are associated with "significantly lower" overall and cause-specific mortality in older male smokers, a study in the November American Journal of Clinical Nutrition finds. "The optimum relative reduction in mortality occurred at alpha-tocopherol levels of 13-14 mg/L," Margaret Wright, Nutritional Epidemiology Branch, National Cancer Institute, et al., write. However, an accompanying editorial by the Linus Pauling Institute's Maret Traber points out it is not known how much vitamin E must be consumed to reach the needed concentration of serum alpha-tocopherol. Wright et al. conducted a cohort study of 29,092 Finnish men who smoke and who had participated in the 1994 Alpha-Tocopherol, Beta Carotene Cancer Prevention Study. The 1994 study showed no statistically significant reduction in lung cancer for smokers taking alpha-tocopherol - the most biologically active and the most prominent of the eight isomers within vitamin E - and found smokers taking high doses of beta carotene had a higher incidence of lung cancer (1"The Tan Sheet" April 18, 1994, p. 1)...
You may also be interested in...
BETA CAROTENE FAILS TO REDUCE LUNG CANCER RISK IN HEAVY SMOKERS enrolled in a Finnish study of 29,133 male long-term smokers aged 50 to 69 years that appears in the April 14 New England Journal of Medicine. In fact, subjects receiving 20 mg beta carotene daily showed an 18% increase in lung cancer incidence. The clinical trial results on beta carotene and vitamin E supplements for the prevention of lung cancer are the first published analyses of the data from the long-term Alpha- Tocopherol, Beta Carotene (ATBC) Cancer Prevention Study.
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.